Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277488/ |